Results 131 to 140 of about 1,580 (184)

Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Sedaghat-Hamedani F, Kayvanpour E, Meder B.   +2 more
europepmc   +1 more source

Antihypertensive Dosing During Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Card Fail Intersect
Reza N, Mahmud N, Austin MA, Duqueney E, Patel P, Boakye E, Hornsby N, DE Feria A, Marzolf A, Owens AT.   +9 more
europepmc   +1 more source

Personalized Sudden Cardiac Death Risk Stratification in Hypertrophic Cardiomyopathy: Beyond Conventional Risk Scores. [PDF]

J Pers Med
Costantino J, Ballatore F, Porcelli D, Romani B, Campoli M, Zuccaro LM, Marchionni G, Alfarano M, Costantino S, Chimenti C.   +9 more
europepmc   +1 more source

Effect of mavacamten on sudden cardiac death risk scores in obstructive hypertrophic cardiomyopathy. [PDF]

ESC Heart Fail
Usai P, Cariou E, Donal E, Eyharts D, Cohen N, Lucas C, Al Wazzan A, Cherbi M, Itier R, Fournier P, Habib G, Lairez O.   +11 more
europepmc   +1 more source

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Targeting Sarcomeric Hypercontractility with Demonstrated Long-Term Safety and Efficacy-A Narrative Review. [PDF]

J Clin Med
Mansour GK, Altebainawi AF, Hajjar AW, Sayed SBH, Alazem FA, Sajid MR.   +5 more
europepmc   +1 more source

Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data. [PDF]

Curr Cardiol Rep
Panichella G, Garofalo M, Ragagnin M, Fanizzi AI, Zampieri M, Del Franco A, Cappelli F, Pieroni M, Olivotto I.   +8 more
europepmc   +1 more source

Hypertrophic Obstructive Cardiomyopathy Present as Acute Myocardial Infarction in a Nonagenarian. [PDF]

JACC Case Rep
Wan X, Zhan Y, Gao Z, Sui Y, Ren J, Chen H, Chang Y, Zhang C, Wang Y.   +8 more
europepmc   +1 more source

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. [PDF]

Heart Fail Rev
Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K.   +4 more
europepmc   +1 more source

ODYSSEY-HCM trial (mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy). [PDF]

Eur Heart J Cardiovasc Pharmacother
Monda E, Limongelli G.
europepmc   +1 more source